Editas Medicine, Inc. — Director's Dealing 2018

Jun 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2018-06-18

Reporting Person: Myer Vickesh (Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-18	Common Stock	M	4300	$0.65	Acquired	4300	Direct
2018-06-18	Common Stock	S	4300	$37.75	Disposed	0	Direct
2018-06-18	Common Stock	M	2700	$0.65	Acquired	2700	Direct
2018-06-18	Common Stock	S	2700	$38.71	Disposed	0	Direct
2018-06-19	Common Stock	M	7000	$11.21	Acquired	7000	Direct
2018-06-19	Common Stock	S	7000	$38.39	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-18	Stock Option (right to buy)	$0.65	M	7000	Disposed	2025-04-29	Common Stock (7000)	Direct
2018-06-19	Stock Option (right to buy)	$11.21	M	7000	Disposed	2025-10-29	Common Stock (7000)	Direct

Footnotes

F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.

F2: This transaction was executed in multiple trades at prices ranging from $37.34 to $38.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $38.35 to $38.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $38.00 to $38.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This option was granted on April 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.

F6: This option was granted on October 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on October 27, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 27, 2019.